| Display title | Chemistry:Rilpivirine |
| Default sort key | Rilpivirine |
| Page length (in bytes) | 20,225 |
| Namespace ID | 3022 |
| Namespace | Chemistry |
| Page ID | 769480 |
| Page content language | en - English |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
| Counted as a content page | Yes |
| Page image |  |
| HandWiki item ID | None |
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
| Page creator | imported>Unex |
| Date of page creation | 06:38, 6 March 2023 |
| Latest editor | imported>Unex |
| Date of latest edit | 06:38, 6 March 2023 |
| Total number of edits | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
Description | Content |
Article description: (description)
This attribute controls the content of the description and og:description elements. | Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with... |
